REDWOOD CITY, CA, USA & SHENZHEN, China I July 29, 2025 I LTZ Therapeutics (“LTZ”), an immunotherapy-focused biotechnology company, today announced a ...

LAVAL, Canada and CUPERTINO, CA, USA I July 29, 2025 I Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and ...

The anti-CD226 mAb adds to Formation Bio’s growing pipeline which currently includes programs in immunology, dermatology, and rheumatology and reflects the company’s focus on first- and best-in-class ...

ETB, is expected to enroll over 500 patients with a primary endpoint of proportion of patients demonstrating functional independence at 90 days and is being conducted under a Special Protocol ...

Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs of ...

Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise ...

US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with Galapagos Purchase price is $55m in cash to be paid upon consummation of the sale with up ...

PARIS, France I July 28, 2025 I Genethon, a worldwide pioneer and leader in research and development in gene therapy for rare genetic diseases, has received ...

Indication SEPHIENCE is indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). SEPHIENCE ...

WALTHAM, MA, USA I July 28, 2025 I Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has ...

LONDON, UK I July 28, 2025 I GSK plc (LSE/NYSE: GSK) today announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to ...

BOLOGNA, Italy I July 28, 2025 I Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT ...